HIV-1 protease is a target of drug development and various inhibitors binding to two Asps in the catalytic site were developed. However, it has a serious drug-resistance, that is, some mutations cause existing inhibitors ineffective, even though hydrolysis reaction of substrate proceeds. To resolve the drug-resistance problem, it is important to clarify difference of recognition mechanism of the protease for inhibitors in the case of native and drug resistance mutational structures, respectively. For indinavir, it is known that mutation (V82T/I84V) greatly affects its binding free energy to HIV-1 protease. We performed QM/MM free energy calculations, and succeeded to determine the protonated states of catalytic Asps and the relative binding...
The current strategy to improve the quality of life of Human Immunodeficiency Virus (HIV) infected i...
The current strategy to improve the quality of life of Human Immunodeficiency Virus (HIV) infected i...
Drug resistance of mutations in HIV-1 protease (PR) is the most severe challenge to the long-term ef...
A human immunodeficiency virus-1 (HIV-1)protease is a homodimeric aspartic protease essential for th...
Despite of a large number of antiretroviral drugs targeting HIV-1 protease for inhibition, mutations...
Despite of a large number of antiretroviral drugs targeting HIV-1 protease for inhibition, mutations...
Despite a large number of antiretroviral drugs targeting HIV-1 protease for inhibition, mutations in...
Despite of a large number of antiretroviral drugs targeting HIV-1 protease for inhibition, mutations...
Human immunodeficiency virus type 1 protease is essential for virus replication and maturation and h...
Despite a large number of antiretroviral drugs targeting HIV-1 protease for inhibition, mutations in...
Despite a large number of antiretroviral drugs targeting HIV-1 protease for inhibition, mutations in...
Darunavir (DRV) is a high affinity (4.5x10(-12) M, DeltaG = -15.2 kcal/mol) HIV-1 protease inhibitor...
The current strategy to improve the quality of life of Human Immunodeficiency Virus (HIV) infected i...
The current strategy to improve the quality of life of Human Immunodeficiency Virus (HIV) infected i...
The current strategy to improve the quality of life of Human Immunodeficiency Virus (HIV) infected i...
The current strategy to improve the quality of life of Human Immunodeficiency Virus (HIV) infected i...
The current strategy to improve the quality of life of Human Immunodeficiency Virus (HIV) infected i...
Drug resistance of mutations in HIV-1 protease (PR) is the most severe challenge to the long-term ef...
A human immunodeficiency virus-1 (HIV-1)protease is a homodimeric aspartic protease essential for th...
Despite of a large number of antiretroviral drugs targeting HIV-1 protease for inhibition, mutations...
Despite of a large number of antiretroviral drugs targeting HIV-1 protease for inhibition, mutations...
Despite a large number of antiretroviral drugs targeting HIV-1 protease for inhibition, mutations in...
Despite of a large number of antiretroviral drugs targeting HIV-1 protease for inhibition, mutations...
Human immunodeficiency virus type 1 protease is essential for virus replication and maturation and h...
Despite a large number of antiretroviral drugs targeting HIV-1 protease for inhibition, mutations in...
Despite a large number of antiretroviral drugs targeting HIV-1 protease for inhibition, mutations in...
Darunavir (DRV) is a high affinity (4.5x10(-12) M, DeltaG = -15.2 kcal/mol) HIV-1 protease inhibitor...
The current strategy to improve the quality of life of Human Immunodeficiency Virus (HIV) infected i...
The current strategy to improve the quality of life of Human Immunodeficiency Virus (HIV) infected i...
The current strategy to improve the quality of life of Human Immunodeficiency Virus (HIV) infected i...
The current strategy to improve the quality of life of Human Immunodeficiency Virus (HIV) infected i...
The current strategy to improve the quality of life of Human Immunodeficiency Virus (HIV) infected i...
Drug resistance of mutations in HIV-1 protease (PR) is the most severe challenge to the long-term ef...